Statement: There was one case of hemorrhaging in the primary trial, and no recorded cases in the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 7/15 (46.67%)   Cardiac arrest * 1/15 (6.67%)   Chest pain - cardiac * 1/15 (6.67%)   Diarrhea * 1/15 (6.67%)   Duodenal hemorrhage * 1/15 (6.67%)   Fatigue * 1/15 (6.67%)   Fever * 1/15 (6.67%)   Sudden death NOS * 1/15 (6.67%)   Sepsis * 1/15 (6.67%)   Skin infection * 1/15 (6.67%)   Neutrophil count decreased * 1/15 (6.67%)   Platelet count decreased * 1/15 (6.67%)
Secondary_evidence: Adverse Events 1:   Total: 69/258 (26.74%)   Anaemia 3/258 (1.16%)   Febrile neutropenia 13/258 (5.04%)   Neutropenia 5/258 (1.94%)   Thrombocytopenia 1/258 (0.39%)   Atrial fibrillation 0/258 (0.00%)   Mitral valve incompetence 1/258 (0.39%)   Pericardial effusion 0/258 (0.00%)   Sinus tachycardia 0/258 (0.00%)   Abdominal pain 3/258 (1.16%)   Abdominal pain upper 1/258 (0.39%)   Colitis 1/258 (0.39%) Adverse Events 2:   Total: 64/224 (28.57%)   Anaemia 2/224 (0.89%)   Febrile neutropenia 4/224 (1.79%)   Neutropenia 1/224 (0.45%)   Thrombocytopenia 0/224 (0.00%)   Atrial fibrillation 1/224 (0.45%)   Mitral valve incompetence 0/224 (0.00%)   Pericardial effusion 2/224 (0.89%)   Sinus tachycardia 1/224 (0.45%)   Abdominal pain 3/224 (1.34%)   Abdominal pain upper 0/224 (0.00%)   Colitis 0/224 (0.00%)